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2364HLA-C*06:02 Allele and Response to
IL-12/23 Inhibition: Results from the
Ustekinumab Phase 3 Psoriasis Program
Katherine Li1, C. Chris Huang1, Bruce Randazzo1, Shu Li1, Philippe Szapary1, Mark Curran1,
Kim Campbell1 and Carrie Brodmerkel1Several small studies suggest that the presence of the human leukocyte antigen (HLA)-Cw6 (C*06:02) allele may
be a predictor of improved response to ustekinumab. This study was designed to assess the association of the
HLA-C*06:02 allele with response to ustekinumab in large cohorts of patients from the phase 3 studies of
ustekinumab in moderate-to-severe psoriasis. In this retrospective study, both HLA-C*06:02-positive and
-negative patients demonstrated good responses to ustekinumab (86% vs. 76%, respectively, achieved at least a
75% improvement from baseline in Psoriasis Area and Severity Index [PASI 75] at week 24). A modestly higher
proportion of HLA-C*06:02-positive than HLA-C*06:02-negative patients achieved PASI 75/90 responses at weeks
12 and 24. The largest response difference between the positive and negative patients (17.9%) was observed for
PASI 75 (week 12), with smaller differences noted at later time points for PASI 90 (11.8% at week 24) and PASI 100
(10.2% at week 28). A differential response to ustekinumab has been confirmed in HLA-C*06:02-positive versus
HLA-C*06:02-negative patients; however, this difference is modest, particularly at the higher response rate
thresholds (PASI 90/100) and later time points (weeks 24/28).
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Psoriasis is a chronic immune-mediated skin disease that is
estimated to affect 2e4% of the population in Western
countries, with a higher prevalence in the United States,
Canada, and Europe compared with other countries
(Christophers, 2001; Gelfand et al., 2005; Kurd and Gelfand,
2008; Parisi et al., 2013). Variability in the prevalence of
psoriasis is due to numerous factors including age, gender,
geography, and ethnicity (Parisi et al., 2013). Psoriasis is a
multifactorial disorder in which complex interactions
between immune pathways, environmental factors, and
genetics play a role in its etiology (Nestle et al., 2009); in fact,
there is strong evidence through genetic epidemiologic
studies that the disease is 60e90% heritable, which is the
greatest reported for multigenic diseases (Elder et al., 1994).
The concordance rate for psoriasis in monozygotic twins
ranges from approximately 35%e73% compared with 6%e
20% in dizygotic twins (Brandrup et al., 1978; Duffy et al.,
1993; Farber et al., 1974; Grjibovski et al., 2007; Lonnberg
et al., 2013). Although greater than 40 psoriasis susceptibil-
ity loci have been identified to date (Nair et al., 2009;
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an open access artPSORS1 genetic locus, a 220-kb region found on chromo-
some 6p21 (Veal et al., 2002), is associated with the greatest
risk for psoriasis, conferring 35e50% of heritability (Basko-
Plluska and Petronic-Rosic, 2012). Within the PSORS1
region, human leukocyte antigen (HLA)-Cw6 has been
identified as the strongest psoriasis susceptibility allele
(Capon et al., 2002; Gudjonsson et al., 2003; Nair et al.,
2006; Zhang et al., 2003).
The HLA-C*06:02 allele is present in 47e64% of patients
with psoriasis and increases the risk of disease by 9- to
23-fold (Feng et al., 2009; Gudjonsson et al. 2003; Okada
et al., 2014; Tiilikainen et al., 1980). The presence of HLA-
C*06:02 is reported to be associated with an earlier onset
of psoriasis, a more severe disease course, and a greater
prevalence of the guttate phenotype (Gudjonsson et al.,
2003, 2006; Mallon et al., 2000). Although the precise
mechanism by which HLA-C*06:02 contributes to disease
etiology is still unclear, HLA-C*06:02 encodes a major his-
tocompatibility complex class I molecule that may be
involved in presentation of autoantigens to CD8þ T cells that
clonally expand in psoriasis lesions (Arakawa et al., 2015). A
disintegrin-like and metalloprotease domain containing
thrombospondin type 1 motif-like 5 has recently been iden-
tified as an HLA-C*06:02-restricted melanocyte-derived
autoantigen that can drive skin-specific psoriatic immune
activation (Arakawa et al., 2015).
At the population level, a significant percentage of
patients with psoriasis do not have the HLA-C*06:02 allele
(Tiilikainen et al., 1980), supporting the assertion that
psoriasis is a multigenic disease in which additional genes
may contribute to susceptibility, including immune-related
genes such as IL-12B, IL-23A, IL-23R, TNFAIP3 and ERAP1
(Eiris et al., 2014; Harden et al., 2015; Strange et al., 2010;s. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is
icle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Psoriasis characteristics in patients across
three studies by HLA-C*06:02 status
HLA-C*06:02-POS
patients (N [ 233)
HLA-C*06:02-NEG
patients (N [ 290) P-value
Age of psoriasis
onset, y
21.4  11.0 27.7  13.6 <0.0001
Disease
duration, y
24.2  12.9 20.3  11.1 0.0003
Baseline PASI
score
18.1  6.5 19.4  6.6 0.0275
Values are reported as mean  SD, unless otherwise noted. P-values are
based on the analysis of variance.
Abbreviations: HLA, human leukocyte antigen; HLA-C*06:02-POS, HLA-
C*06:02-positive; HLA-C*06:02-NEG, HLA-C*06:02-negative; PASI,
Psoriasis Area and Severity Index.
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HLA-C*06:02 Allele and Response to UstekinumabTejasvi et al., 2012). Because of the genetic complexity of
psoriasis, there is significant variability in the clinical pre-
sentation of the disease (Griffiths et al., 2007). Likewise,
different types of psoriasis do not always respond to the same
treatment, and even within the same type of disease, there
are responders and nonresponders to each treatment
(Talamonti et al., 2013). Although biological agents have
significantly contributed to advancements in the clinical
management of psoriasis, use of these treatments is associ-
ated with varying degrees of efficacy, safety, risk, and cost. As
a result, the identification of pharmacogenetic biomarkers
that could improve treatment outcomes and/or minimize
significant side effects is desirable. However, little is known
about the link between pharmacogenetics and biological
therapies in psoriasis (Ryan et al., 2011). Patients with pso-
riasis positive for HLA-C*06:02 have been suggested to have
significantly higher response rates to efalizumab (anti-
CD11a) (Gulliver, 2009). The association between HLA-
C*06:02 and response to tumor necrosis factor (TNF)
inhibitors is not well understood; however, it has been
reported that patients expressing two single nucleotide
polymorphisms in the gene encoding TNFAIP3 have good
responses to TNF therapies (Tejasvi et al., 2012). To date,
although these markers have been suggested to be associated
with response, no genetic markers have been confirmed to be
associated with response to biological therapies in large well-
defined cohorts of patients with psoriasis.
Ustekinumab is a fully human monoclonal antibody that
targets the common p40 subunit of the IL-12 and IL-23 cy-
tokines. Multiple clinical trials have demonstrated the clin-
ical utility of ustekinumab in the treatment of moderate-to-
severe psoriasis (Griffiths et al., 2010; Leonardi et al., 2008;
Papp et al., 2008) and psoriatic arthritis (McInnes et al.,
2013; Ritchlin et al., 2014). It was recently reported in a
small cohort of 51 patients with psoriasis that the HLA-
C*06:02 allele was associated with a rapid and beneficial
clinical response to ustekinumab (Talamonti et al., 2013,
2016). In the current study, we report the results from a
retrospective study conducted to evaluate the role of HLA-
C*06:02 and the response to ustekinumab in a large cohort
of patients with psoriasis (n ¼ 601) who originally partici-
pated in the phase 3 clinical trials PHOENIX 1 (Leonardi
et al., 2008), PHOENIX 2 (Papp et al., 2008), and ACCEPT
(Griffiths et al., 2010).
RESULTS
The prevalence of the HLA-C*06:02 genotype in this study
consisting of patients with moderate-to-severe plaque psori-
asis from the PHOENIX 1, PHOENIX 2, and ACCEPT
randomized, controlled clinical studies was 44.6%
(Supplementary Table S1 online). Patient baseline
demographics and disease characteristics were similar across
the three studies. Across studies, similar proportions of pa-
tients achieved a Psoriasis Area and Severity Index (PASI) 75
response at week 12 (the primary endpoint for each study).
HLA-C*06:02-positive (POS) in the combined population
was associated with longer disease duration, an earlier age of
onset, and with modestly lower baseline PASI scores
compared with patients who were HLA-C*06:02-negative
(NEG) (Table 1). There were no significant associations ofHLA-C*06:02 with other disease characteristics such as scalp
psoriasis (data not shown).
The association of HLA-C*06:02 and clinical response to
ustekinumab was assessed measuring 50/75/90/100%
improvement from baseline in PASI (PASI 50, PASI 75, PASI
90, and PASI 100) (Figure 1) and physician global assessment
responses (Supplementary Figure S1 online). Because similar
results were observed in patients who received ustekinumab
45 or 90 mg treatment (data not shown), the two dose groups
were combined in this analysis to yield a larger sample size.
A higher percentage of HLA-C*06:02-POS patients achieved
PASI 50, 75, 90, and 100 responses at weeks 4, 12, 24, and
28 compared with HLA-C*06:02-NEG patients (Figure 1).
However, the difference was modest, reaching significance
for PASI 50 responses at weeks 4 (Figure 1a), as well as PASI
75 responses at weeks 4 and 12 (Figure 1b). The difference in
PASI responses between HLA-C*06:02-POS and HLA-
C*06:02-NEG patients ranged from 0e17.9%, whereas the
difference between the overall population (i.e., regardless of
genotype) and the HLA-C*06:02-POS population ranged
from 0e10.4% (Figure 1). The largest response difference
between the POS and NEG patients (17.9%) or the overall
population (10.4%) was observed for PASI 75 at week 12.
Similarly, a greater proportion of HLA-C*06:02-POS patients
achieved a physician global assessment score of 0 or 1
(cleared or minimal) than HLA-C*06:02-NEG patients
(Figure S1 online), only reaching significance at week 4 with
a difference of 15% between HLA-C*06:02-POS and HLA-
C*06:02-NEG patients.
When patients were stratified by the recommended weight-
based dosing paradigm (ustekinumab 45 mg for patients
<100 kg; ustekinumab 90 mg for patients 100 kg), the
differences in PASI 75 response by HLA-C*06:02 were
slightly magnified, especially in the 100 kg subpopulation
with a range of 0e15.9% when compared with the overall
population and the HLA-C*06:02-POS patients (Figure 2).
Patients were also stratified by prior treatment with anti-TNF
agents. The largest response differences between HLA-
C*06:02-POS patients and the overall population observed in
anti-TNF-naı¨ve and anti-TNF-experienced patients were
10.8% at week 4 and 6.7% at week 24, respectively
(Figure 3), demonstrating that HLA-C*06:02 status did not
differentially influence PASI 75 response based on prior anti-
TNF exposure.www.jidonline.org 2365
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HLA-C*06:02-NEG 0.00 10.36 62.69 76.35 72.30
Overall 1.21 16.36 70.18 80.39 74.02
δ POS vs. NEG 4.44 14.37 6.08 7.75 4.60
δ POS vs. Overall 2.59 8.40 3.54 4.50 2.68
2.90 14.46 17.89 9.63 4.12
1.69 8.46 10.40 5.59 2.40
Week 2 4 12 24 28
N 331 330 332 255 254
HLA-C*06:02-POS 1.45 5.84 46.76 64.49 54.72
HLA-C*06:02-NEG 0.00 2.59 40.93 52.70 50.00
Overall 0.60 3.94 43.37 57.65 51.97
Week 2 4 12 24 28
N 331 330 332 255 254
HLA-C*06:02-POS 0.00 2.19 20.14 35.51 31.13
HLA-C*06:02-NEG 0.00 0.52 14.51 26.35 20.95
Overall 0.00 1.21 16.87 30.20 25.20
δ POS vs. NEG 1.45 3.25 5.83 11.79 4.72
δ POS vs. Overall 0.85 1.90 3.39 6.84 2.75
δ POS vs. NEG 0.00 1.67 5.63 9.16 10.18
δ POS vs. Overall 0.00 0.98 3.27 5.31 5.93
δ POS vs. NEG
δ POS vs. Overall
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Figure 1. Psoriasis Area and Severity
Index (PASI) response by human
leukocyte antigen (HLA)-C*06:02
status. The proportion of HLA-
C*06:02-positive (POS) and -negative
(NEG) patients achieving a (a) 50%
improvement in PASI from baseline
(PASI 50); (b) PASI 75 response; (c)
PASI 90 response; (d) PASI 100
response following ustekinumab
treatment (45 and 90 mg dose groups
combined). *P < 0.05 based on
adjusted Fisher’s exact test; d,
difference between values.
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2366The association of HLA-C*06:02 and long-term efficacy
was also assessed in the long-term extension of the PHOENIX
1 and PHOENIX 2 studies. The PHOENIX 1 study population
was used to assess efficacy rates by HLA-C*06:02 status in
patients at their 5-year final efficacy assessment (Table 2). In
general, HLA-C*06:02-POS patients had modestly higher
efficacy rates than HLA-C*06:02-NEG patients, with statisti-
cal significance for PASI 50 (92.8% HLA-C*06:02-POS vs.
80.5% HLA-C*06:02-NEG) and PASI 75 (82.6% HLA-
C*06:02-POS vs. 64.4% HLA-C*06:02-NEG) response rates.
The PHOENIX 2 study evaluated dosing adjustment either by
dose (ustekinumab 45 to 90 mg), or by dose interval (every 12
weeks to every 8 weeks). Compared with HLA-C*06:02-POS
patients, a modestly greater proportion of HLA-C*06:02-NEG
patients experienced an adjustment in dosing interval (every
12 weeks to every 8 weeks) (49.5% vs. 42.6%; Table 3), or an
adjustment in dosing interval and dose (45 to 90 mg) (41.4%
vs. 32.6%; Table 3). Consistent with this pattern, a slightly
larger proportion of HLA-C*06:02-POS patients (57.5%) did
not receive any adjustment in dosing interval or doseJournal of Investigative Dermatology (2016), Volume 136compared with HLA-C*06:02-NEG (50.5%) patients
(Table 3).
DISCUSSION
Through genome-wide association studies, greater than 40
susceptibility loci for psoriasis have been identified,
including polymorphisms in genes associated with innate
and adaptive immunity (TRAF3IP2, IL-23R, IL-12B, ERAP1,
STAT3, and TYK2, among others) (Nair et al., 2009; Strange
et al., 2010; Sun et al., 2010; Tsoi et al., 2015). Genetic
variations in these genes highlight the importance of antigen
presentation, the IL-12/23 axis, and T cells in psoriasis, but
polymorphisms in some of these genes have been correlated
with response to biological treatments. For example, two
single-nucleotide polymorphisms in the gene encoding
TNFAIP3 have been correlated with response to TNF blockers
(Tejasvi et al., 2012). Recently, the utility of HLA-C*06:02 as
a pharmacogenetic marker of treatment response to usteki-
numab, an IL-12/IL-23p40 inhibitor, has been explored
(Talamonti et al., 2016).
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HLA-C*06:02-NEG 0.00 15.15 62.12 77.19 75.44
Overall 0.91 19.09 70.91 81.05 73.68
Week 2 4 12 24 28
N 58 58 58 37 37
HLA-C*06:02-POS 0.00 19.05 76.19 92.86 71.43
HLA-C*06:02-NEG 0.00 2.70 51.35 69.57 65.22
Overall 0.00 8.62 60.34 78.38 67.57
δ POS vs. NEG 2.30 9.80 22.00 9.60 -4.30
δ POS vs. Overall 1.30 5.90 13.10 5.70 -2.60
δ POS vs. NEG 0.00 16.40 24.80 23.30 6.20
δ POS vs. Overall 0.00 10.50 15.90 14.50 3.80
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Figure 2. Psoriasis Area and Severity
Index (PASI) response by weight-
based dosing. The proportion of
human leukocyte antigen (HLA)-
C*06:02-positive (POS) and -negative
(NEG) patients achieving a 75%
improvement in PASI from baseline
(PASI 75) based on weight-based
dosing. (a) Patients weighing <100 kg
received ustekinumab 45 mg and (b)
patients weighing 100 kg received
ustekinumab 90 mg. d, difference
between values.
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HLA-C*06:02 Allele and Response to UstekinumabIn our study, the association of the HLA-C*06:02 with
response to ustekinumab was confirmed and further explored
in a relatively large cohort of well-phenotyped patients with
moderate-to-severe psoriasis from three randomized
placebo-controlled clinical trial populations (Griffiths et al.,
2010; Leonardi et al., 2008; Papp et al., 2008). There was
not a strong association with HLA-C*06:02 and maximal
clinical response (PASI 90/PASI 100) to ustekinumab, and
there was modest association with early clinical response
(weeks 2e12) and good clinical response (PASI 75) that
decreased over time. The logistic regression analysis evalu-
ated 10 single nucleotide polymorphisms representing
T helper type 17 pathway genes IL-23R, IL-23A, and IL-12B
and found no significant association between any of these
single nucleotide polymorphisms and PASI 75 or PASI 90
response to ustekinumab. Interactions of these genes and
HLA-C*06:02 did not predict PASI 75 or PASI 90 responses to
ustekinumab better than HLA-C*06:02 alone. Although the
differences between HLA-C*06:02-POS and HLA-C*06:07
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Week 2 4 12 24 28
N 226 226 227 157 156
HLA-C*06:02-POS 2.97 30.69 88.24 91.55 80.00
HLA-C*06:02-NEG 0.00 11.20 69.60 84.88 81.40
Overall 1.33 19.91 77.97 87.90 80.77
Week
N
HLA-C*06:02-POS
HLA-C*06:02-NEG
Overall
δ POS vs. NEG 2.97 19.49 18.64 6.67 -1.40
δ POS vs. Overall 1.64 10.78 10.27 3.65 -0.77
δ POS vs. NEG
δ POS vs. Overall
*
* HLA-C*06:02-POS
HLA-C*06:02-NEG
Overall02-NEG patients was clearly discernable when comparing
the overall population versus HLA-C*06:02-POS patients, the
increase in efficacy for the HLA-C*06:02-POS population
was minimal (approximately 10% or less). Therefore, the
results from this retrospective study suggest that utilization of
HLA-C*06:02 status for determining treatment may have
limited clinical utility.
The prevalence of HLA-C*06:02 among North American
patients sampled in this study, 41.9% (139 of 332) in
ustekinumab-treated patients and 44.6% (233 of 532) in the
overall cohort, is at the lower end of the reported range for
white patients with psoriasis (42e66.9%) (Enerba¨ck et al.,
1997; Gudjonsson et al., 2002; O’Brien et al., 2001;
Tiilikainen et al., 1980). There is a potential bias in retro-
spective studies by unbalanced participation of patients with
a positive clinical trial experience. Of the patients who were
approached to provide DNA samples for this retrospective
analysis, the overall participation rate was high, approxi-
mately 80%. In addition, the clinical response rates of the07
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Figure 3. Psoriasis Area and Severity
Index (PASI) response by tumor
necrosis factor (TNF) status. The
proportion of TNF-naı¨ve (a) and TNF-
experienced (b) patients achieving a
75% improvement in PASI from
baseline (PASI 75) after ustekinumab
treatment (45 and 90 mg dose groups
combined). *P < 0.05 based on
adjusted Fisher’s exact test; d,
difference between values.
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Table 2. Long-term efficacy in PHOENIX 1 patients
receiving at least one dose of ustekinumab through
5 years
HLA-C*06:02-POS
patients (N [ 69)
HLA-C*06:02-NEG
patients (N [ 87)
Total
(N [ 156)
PASI response,
n (%)
PASI 50 64 (92.8)1,2 70 (80.5)1 134 (85.9)
PASI 75 57 (82.6)1,2 56 (64.4)1 113 (72.4)
PASI 90 36 (52.2)1 36 (41.4) 72 (46.2)
PASI 100 18 (26.1)1 19 (21.8) 37 (23.7)
PGA score
of 0 or 1
37 (53.6)1 39 (44.8) 76 (48.7)
Abbreviations: HLA, human leukocyte antigen; HLA-C*06:02-POS, HLA-
C*06:02-positive; HLA-C*06:02-NEG, HLA-C*06:02-negative; PASI 50/
75/90/100, at least a 50/75/90/100% improvement from baseline in
Psoriasis Area and Severity Index (PASI); PGA, Physician’s Global
Assessment.
1HLA-C*06:02 status with higher response rate for a given endpoint.
2Fisher’s exact test P-value < 0.05.
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2368patients who provided DNA samples for this analysis are
similar to the overall response rates for each clinical trial
(PHOENIX 1, PHOENIX 2, and ACCEPT) when assessing the
primary endpoint, indicating that despite the potential for
selection bias, the patients included in this analysis are likely
representative of the overall trial populations.
Methods to predict response to therapy are an important
focus for immune-mediated diseases, as clinical manifesta-
tions of the disease may be similar across a population.
However, the disease mechanisms could differ within a
population, resulting in different responses in individual pa-
tients to the same therapy. Identifying patients who are more
likely to respond or have a maximal response to a specific
therapy or mechanism of action would be a significant
advancement in the psoriasis treatment paradigm. However,
efforts to identify predictors of response in immune-mediated
diseases have been largely unsuccessful. When potential
predictors have been discovered, the subsequent replication
of results in independent cohorts of patients has not been
pursued, or the replication has failed to demonstrate clini-
cally relevant separation of responders and nonresponders toTable 3. Proportion of patients from the PHOENIX 2 study
dosing interval (every 12 weeks to every 8 weeks) adjustm
HLA
Adjustment in dosing interval (ustekinumab q12w to q8w)
N
n (%)
Adjustment in dosing interval (q12w to q8w) and dose (45 to 90 mg)
N
n (%)
No adjustment in dosing interval or dose
N
n (%)
Abbreviations: HLA, human leukocyte antigen; HLA-C*06:02-POS, HLA-C*06
weeks; q12w, every 12 weeks.
1Based on Fisher’s exact test between groups with vs. without dose/dosing inte
Journal of Investigative Dermatology (2016), Volume 136treatment (Ryan et al., 2011). This is likely due to immune
diseases being driven by a combination of genetics and
environmental factors, with no single factor acting as a pri-
mary driver. Psoriasis is unique in the family of immune-
mediated diseases in that the clinical response to current
biological therapies with related mechanisms of action is
high (Nast et al., 2015). This differs from other immune-
mediated diseases such as rheumatoid arthritis (Valesini
et al., 2008) or inflammatory bowel disease (Peyrin-Biroulet
and Lemann, 2011) in which, on average, fewer than 50%
of patients achieve a good response and even fewer achieve a
maximal response, such as remission. The high clinical
response rates observed in patients with psoriasis points to a
common mechanism driving disease in the majority of
patients. Therefore, identifying a robust predictor of response
that distinguishes true nonresponders or suboptimal
responders remains a significant challenge, one that will
likely require multiple factors and may not be limited to one
genetic factor such as HLA-C*06:02. It is also unlikely that
the predictor would be specific to a given therapeutic agent
given the overlap in mechanisms of action among many of
the current biologics (i.e., anti-IL-12p40, anti-IL-23p19, and
anti-IL-17).
The association of the HLA-C*06:02 allele with response to
ustekinumab has now been replicated in two independent
cohorts; however, the magnitude of the level of efficacy
achieved based on HLA-C*06:02 status has varied (Chiu
et al., 2014; Talamonti et al., 2013). One study that evalu-
ated 51 patients with psoriasis reported that 96.4% of HLA-
C*06:02-POS patients achieved a PASI 75 response at week
12, compared with 65.2% of HLA-C*06:02-NEG patients
(Talamonti et al., 2013). A difference was also noted for the
higher response rate of PASI 90, with 85.7% of HLA-C*06:02-
POS patients achieving PASI 90 at week 12 compared with
56.5% of HLA-C*06:02-NEG patients (Talamonti et al.,
2013). Another study of a Chinese population with a lower
incidence of HLA-C*06:02-POS patients (8 of 66; 12%) re-
ported that 75% of HLA-C*06:02-POS patients achieved a
PASI 75 response compared with 45% of HLA-C*06:02-NEG-
patients after 16 weeks of ustekinumab treatment (Chiu et al.,
2014). The reasons for variability in reported rates may be
attributed to several factors that differed between thewho experienced dose (ustekinumab 45 to 90 mg) and
ent by HLA-C*06:02 status
-C*06:02-POS patients HLA-C*06:02-NEG patients P-value1
94 107
40 (42.6) 53 (49.5) 0.3951
43 58
14 (32.6) 24 (41.4) 0.1883
94 107
54 (57.5) 54 (50.5) e
:02-positive; HLA-C*06:02-NEG, HLA-C*06:02-negative; q8w, every 8
rval adjustment.
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HLA-C*06:02, early onset psoriasis, sex, and baseline disease
severity. One key factor may be that the small studies were
open-label (Talamonti et al., 2013) with patients exhibiting
higher PASI 75 responses rates at week 12 (80.8%) than the
patients in the current analysis from the randomized,
placebo-controlled studies from the phase 3 ustekinumab
clinical trials (70.2%). A recently published retrospective
study assessing long-term outcomes reported that 18% more
HLA-C*06:02-POS patients than HLA-C*06:02-NEG patients
achieved at least a PASI 75 response at 3 years (Talamonti
et al., 2016). These results are comparable with our find-
ings in which 18.2% more HLA-C*06:02-POS patients than
in the HLA-C*06:02-NEG population achieved a PASI 75
response at 5 years.
The push toward personalized medicine in patients with
psoriasis and other immune-mediated diseases will benefit
from the use of large, independent cohorts of well-
characterized patients with objective measures of response
and sufficient exposure to therapy to identify predictors of
response in these complex heterogeneous diseases. The re-
sults of this study establish that patients with moderate-to-
severe psoriasis who have the HLA-C*06:02 allele exhibit a
modest increase in likelihood of response to ustekinumab,
especially at early time points and lower response thresholds
compared with patients who do not. The biological rationale
for this is unknown and may be related to HLA-C*06:02 and/
or other unknown factors. Practically, the modest difference
in response between HLA-C*06:02-POS patients and HLA-
C*06:02-NEG patients over longer periods of time and at the
increasingly relevant, higher response thresholds does not
provide a clear rationale for using HLA-C*06:02 genotyping
for directing the choice of therapy.
MATERIAL AND METHODS
Patients
North American study participants randomized and treated in at
least one of the following ustekinumab psoriasis phase 3 studies,
PHOENIX 1 (Leonardi et al., 2008), PHOENIX 2 (Papp et al., 2008),
and ACCEPT (Griffiths et al., 2010), were approached for permission
and the retrospective collection of DNA samples. Every patient who
agreed to participate in the retrospective study provided two buccal
swab samples for DNA and Institutional Review Board-approved
written informed consent. Overall, samples were obtained from a
total of 601 patients. Of the 601 patients, 523 of European descent
were used to assess the association between HLA-C*06:02 status
and psoriasis characteristics, and 332 patients of European descent
who had been randomized to receive ustekinumab treatment at
baseline in their respective trials were assessed for the HLA-C*06:02
association with ustekinumab response.
PHOENIX 1 (Leonardi et al., 2008) and PHOENIX 2 (Papp et al.,
2008) are randomized placebo-controlled studies in which patients
with moderate-to-severe psoriasis received ustekinumab for up to 5
years (Langley et al., 2015; Papp et al., 2013). The ACCEPT study
(Griffiths et al., 2010) compared the efficacy and safety of usteki-
numab versus etanercept for the treatment of moderate-to-severe
plaque psoriasis for up to 44 weeks of treatment. From PHOENIX
1 and PHOENIX 2, only patients who received ustekinumab 45
or 90 mg at week 0 were included in the analysis, excludingplacebo-treated patients who crossed over to receive ustekinumab at
week 12. For the ACCEPT study, only data from ustekinumab-treated
patients in the active comparator-controlled portion (through week
12) were included in this report.
Patients from PHOENIX 1 who received at least one dose of
ustekinumab were used to evaluate the association between HLA-
C*06:02 status and long-term efficacy, up to week 244. PHOENIX
2 data were used to evaluate HLA-C*06:02 status and the need for
dose escalation.
DNA extraction and genotyping
DNA extraction was completed using a buccal swab isolation kit
(IsoHelix, Harrietsham, Kent, UK). DNA quality and integrity was
checked before applying to genotyping processing. Samples were
genotyped by two independent methods: (i) the HumanOmni2.5-8
(Omni2.5) BeadChip from Illumina (San Diego, CA) in accordance
with the manufacturer’s instructions. The Omni2.5 chip features
approximately 2.5 million markers that capture variants down to
minor allele frequency of 2.5% across diverse human populations;
(ii) sequence-specific primer polymerase chain reaction as described
previously (Talamonti et al., 2013). DNA extraction and genotyping
were performed by Expression Analysis (Durham, NC). Both impu-
tation and the sequence specific PCR methods were utilized to
determine HLA-C*06:02 status, and the two methods are more than
95% concordant (Supplementary Table S2 online). Therefore, only
the data utilizing the imputation method are presented.
HLA imputation
The SNP2HLA software package (http://www.broadinstitute.org/
mpg/snp2hla/) was used to impute the HLA-C genotypes from the
Omni2.5 chip data. The allele counts were dichotomized to Cw6-
POS (patients with one or two copies of *06:02) or Cw6-NEG
(patients with other HLA-C alleles). Note that this algorithm uses a
panel of samples from white patients as a reference, and thus only
523 patients of European descent were included in this study (Jia
et al., 2013). Principal component analysis was used to determine
the genetic ancestry of the study patients.
Data analysis
Statistical analysis was conducted using ArrayStudio v9 (OmicSoft,
Cary, NC). Similarity in patient demographics and psoriasis char-
acteristics was assessed by the analysis of variance before clinical
data from PHOENIX 1, PHOENIX 2, and ACCEPT were merged for
analysis. Clinical data from all three trials were merged for assess-
ments at weeks 2, 4, and 12, whereas only data from PHOENIX 1
and PHOENIX 2 were merged for assessments at weeks 24 and 28.
Clinical responses to ustekinumab were analyzed and summarized
by HLA-C*06:02 status (e.g., HLA-C*06:02-POS vs. HLA-C*06:02-
NEG) over time. A two-tailed Fisher’s exact test was conducted at
each selected time point to compare the proportion of patients who
achieved a clinical response to ustekinumab between patients with
different genetic factor status. Benjamini-Hochberg false discovery
rate was applied for multiple testing correction. Associations with
Benjamini-Hochberg false discovery rate-adjusted P-values <0.05
were considered significant.
One-way analysis of variance was conducted to compare HLA-
C*06:02-POS and -NEG patients in baseline psoriasis disease char-
acteristics including age of onset, disease duration, and baseline
PASI scores. Differences with P-value <0.05 were considered
significant.www.jidonline.org 2369
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